Access to quality diagnosis, treatment, and prevention for tuberculosis (TB) is a human right. Are the necessary tests, treatments, vaccines, services and policies available where you live or work? This new checklist from Treatment Action Group (TAG) lays out simply…
TAG's annual Report on Tuberculosis Research Funding Trends tracks how much public, private, philanthropic, and multilateral institutions spend on TB research and development (R&D) across six areas of research: basic science, diagnostics, drugs vaccines, operational research, and infrastructure/unspecified projects. The…
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
August 27, 2019 – This policy brief was developed by TAG and the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), and it details how children with TB are affected by the pediatric research exemption for orphan drugs. The brief also proposes…
Treatment Action Group (TAG) welcomes a report released last week by the U.S. Food and Drug Administration (FDA) that highlights urgent gaps in pediatric research. This report confirms that we are missing critical information necessary to treat children affected by orphan diseases.
TAG's TB Activist Toolkits provide fundamental information about tuberculosis (TB) in order to strengthen global advocacy and understanding of the latest innovations, evidence, and guidance around TB and TB/HIV. These toolkits cover important base knowledge on TB and TB/HIV, as well…
Treatment Action Group (TAG) strongly opposes the administration’s finalized rule “Inadmissibility on Public Charge Grounds.” This rule, which goes into effect on October 15, 2019, dangerously expands the definition of immigrants who are ineligible for admission into the U.S. or adjustment of status to include those who seek basic public services for health, nutrition, and housing.
Treatment Action Group welcomes simpler, shorter treatment options for people with some forms of drug-resistant tuberculosis, while urging additional research and equitable access.
June 2013 Where are we going, where have we been? By Mike Frick Since the 2012 Pipeline Report, results from phase II trials and advances in preclinical development have brought the pipeline for new TB vaccines into sharper focus, even…
June 2013 Better than Ever Is Not Good Enough By Erica Lessem NOTE: a postscript section at the end of this article includes periodic updates since publication in June 2013. Introduction In December 2012, tuberculosis (TB) treatment reached a historic…